Mia's Feed
Medical News & Research

Discovery of a Cellular Network Accelerating Liver Fibrosis

Discovery of a Cellular Network Accelerating Liver Fibrosis

Share this article

Scientists at Toho University have identified a novel intercellular communication network involving FGF18 and osteopontin that accelerates liver fibrosis, offering new targets for treatment of chronic liver diseases.

2 min read

Recent research by scientists at Toho University has uncovered a novel intercellular communication system that plays a significant role in the progression of liver fibrosis, a condition characterized by scarring and stiffening of the liver tissue. Liver fibrosis commonly results from chronic liver diseases such as hepatitis and metabolic-associated steatohepatitis (MASH). If left untreated, advanced fibrosis can lead to severe complications including cirrhosis and liver cancer, emphasizing the importance of understanding its underlying mechanisms.

Led by Dr. Takao Seki and Dr. Hiroyasu Nakano, the study published in iScience reveals how hepatic stellate cells, which normally store vitamin A, transform into myofibroblasts during liver injury. These activated stellate cells are responsible for producing collagen and other extracellular matrix components that contribute to fibrosis. The researchers identified that the growth factor FGF18 stimulates these stellate cells to produce osteopontin (OPN), a molecule that further amplifies fibrotic activity.

The study demonstrates that OPN influences neighboring quiescent stellate cells, inducing their activation and creating a feedback loop that propagates fibrosis. Notably, OPN targets only the dormant stellate cells and not those already activated, which suggests a mechanism for the stepwise spread of fibrosis within the liver. Using mouse models, the team found that OPN signals through a receptor called integrin, promoting intercellular communication that accelerates scarring.

This discovery points to a complex, dynamic system driven by specific cell signals, challenging the traditional view of fibrosis as a simple consequence of certain molecules. It highlights the potential of targeting the FGF18–OPN pathway for therapeutic intervention. Since FGF18 acts specifically on hepatic stellate cells, drugs designed to disrupt this axis could provide precise treatment options with fewer side effects compared to conventional therapies.

Overall, this research advances our understanding of liver fibrosis's cellular processes and opens new avenues for developing targeted therapies to combat chronic liver diseases. The collaborative effort involved contributions from other experts, including Dr. Yuichi Tsuchiya and Dr. Minoru Tanaka, further emphasizing the significance of these findings for future clinical applications.

Source: https://medicalxpress.com/news/2025-06-cellular-communication-network-liver-fibrosis.html

Stay Updated with Mia's Feed

Get the latest health & wellness insights delivered straight to your inbox.

How often would you like updates?

We respect your privacy. Unsubscribe at any time.

Related Articles

New Research Reveals GADD45A Protein's Role in Preventing Heart Failure

Emerging research identifies the GADD45A protein as a key factor in preventing cardiac hypertrophy and heart failure. Boosting GADD45A activity may offer new therapeutic avenues for heart disease management.

Investigation Uncovers Data Inaccuracies in Key Studies of Heart Medication Ticagrelor

A recent investigation by The BMJ highlights serious data discrepancies in pivotal studies supporting the approval of the widely used heart medication ticagrelor, raising concerns over its safety and efficacy.

Could Caffeine Play a Role in Preventing Sudden Infant Death Syndrome?

Research suggests caffeine might help prevent Sudden Infant Death Syndrome by counteracting low oxygen episodes in infants. This innovative hypothesis could open new pathways for prevention strategies in infant health.